These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36641439)

  • 1. A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice.
    Barendrecht S; Schreurs A; Geissler S; Sabanov V; Ilse V; Rieckmann V; Eichentopf R; Künemund A; Hietel B; Wussow S; Hoffmann K; Körber-Ferl K; Pandey R; Carter GW; Demuth HU; Holzer M; Roßner S; Schilling S; Preuss C; Balschun D; Cynis H
    Alzheimers Res Ther; 2023 Jan; 15(1):16. PubMed ID: 36641439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice.
    Farfara D; Sooliman M; Avrahami L; Royal TG; Amram S; Rozenstein-Tsalkovich L; Trudler D; Blanga-Kanfi S; Eldar-Finkelman H; Pahnke J; Rosenmann H; Frenkel D
    J Neuroinflammation; 2023 Jul; 20(1):174. PubMed ID: 37496076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer's Disease.
    Tok S; Maurin H; Delay C; Crauwels D; Manyakov NV; Van Der Elst W; Moechars D; Drinkenburg WHIM
    Acta Neuropathol Commun; 2022 Jun; 10(1):92. PubMed ID: 35739575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
    Guo Q; Li H; Cole AL; Hur JY; Li Y; Zheng H
    PLoS One; 2013; 8(11):e80706. PubMed ID: 24278307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in Tau Pathology in P290S
    Huang M; Macdonald J; Lavenir I; Chen R; Craxton M; Slavik-Smith E; Davies SW; Goedert M
    eNeuro; 2022; 9(6):. PubMed ID: 36635241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
    DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
    Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.
    Saul A; Sprenger F; Bayer TA; Wirths O
    Neurobiol Aging; 2013 Nov; 34(11):2564-73. PubMed ID: 23747045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer's Disease Mouse Models.
    Gannon M; Wang B; Stringfellow SA; Quintin S; Mendoza I; Srikantha T; Roberts AC; Saito T; Saido TC; Roberson ED; Yacoubian TA
    eNeuro; 2022; 9(3):. PubMed ID: 35697511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways.
    Ibanez KR; McFarland KN; Phillips J; Allen M; Lessard CB; Zobel L; De La Cruz EG; Shah S; Vo Q; Wang X; Quicksall Z; Ryu D; Funk C; Ertekin-Taner N; Prokop S; Golde TE; Chakrabarty P
    Alzheimers Res Ther; 2022 Jul; 14(1):104. PubMed ID: 35897046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease.
    Stancu IC; Ris L; Vasconcelos B; Marinangeli C; Goeminne L; Laporte V; Haylani LE; Couturier J; Schakman O; Gailly P; Pierrot N; Kienlen-Campard P; Octave JN; Dewachter I
    FASEB J; 2014 Jun; 28(6):2620-31. PubMed ID: 24604080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
    Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
    J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
    Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
    Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse.
    Dinkins MB; Enasko J; Hernandez C; Wang G; Kong J; Helwa I; Liu Y; Terry AV; Bieberich E
    J Neurosci; 2016 Aug; 36(33):8653-67. PubMed ID: 27535912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small-molecule microtubule-stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease.
    Yao Y; Muench M; Alle T; Zhang B; Lucero B; Perez-Tremble R; McGrosso D; Newman M; Gonzalez DJ; Lee VM; Ballatore C; Brunden KR
    Alzheimers Dement; 2024 Jul; 20(7):4540-4558. PubMed ID: 38884283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of brain and cerebellar proteomes linked to Aβ and tau pathology in a female triple-transgenic murine model of Alzheimer's disease.
    Ciavardelli D; Silvestri E; Del Viscovo A; Bomba M; De Gregorio D; Moreno M; Di Ilio C; Goglia F; Canzoniero LM; Sensi SL
    Cell Death Dis; 2010 Oct; 1(10):e90. PubMed ID: 21368863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.
    Devi L; Tang J; Ohno M
    Curr Alzheimer Res; 2015; 12(1):13-21. PubMed ID: 25523425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.